The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma

被引：63

作者：

Garcia-Reyes, Balbina ^{[1
]}

Kretz, Anna-Laura ^{[1
]}

Ruff, Jan-Philipp ^{[1
]}

von Karstedt, Silvia ^{[2
,3
]}

Hillenbrand, Andreas ^{[1
]}

Knippschild, Uwe ^{[1
]}

Henne-Bruns, Doris ^{[1
]}

Lemke, Johannes ^{[1
]}

机构：

[1] Ulm Univ Hosp, Dept Gen & Visceral Surg, Albert Einstein Allee 23, D-89081 Ulm, Germany

[2] Univ Hosp Cologne, Dept Translat Genom, Weyertal 115b, D-50931 Cologne, Germany

[3] Univ Cologne, Cologne Excellence Cluster Cellular Stress Respon, Joseph Stelzmann Str 26, D-50931 Cologne, Germany

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2018年 / 19卷 / 10期

关键词：

pancreatic cancer; pancreatic ductal adenocarcinoma; CDK; cyclin-dependent kinase; INHIBITOR DINACICLIB MK-7965; CHRONIC LYMPHOCYTIC-LEUKEMIA; TRAIL-INDUCED APOPTOSIS; I DOSE-ESCALATION; CELL-CYCLE; PROTEIN-KINASE; S-PHASE; DNA-DAMAGE; REPLICATION STRESS; ANTITUMOR-ACTIVITY;

D O I：

10.3390/ijms19103219

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The family of cyclin-dependent kinases (CDKs) has critical functions in cell cycle regulation and controlling of transcriptional elongation. Moreover, dysregulated CDKs have been linked to cancer initiation and progression. Pharmacological CDK inhibition has recently emerged as a novel and promising approach in cancer therapy. This idea is of particular interest to combat pancreatic ductal adenocarcinoma (PDAC), a cancer entity with a dismal prognosis which is owed mainly to PDAC's resistance to conventional therapies. Here, we review the current knowledge of CDK biology, its role in cancer and the therapeutic potential to target CDKs as a novel treatment strategy for PDAC.

引用

页数：28

共 249 条

[1] TFIIH is negatively regulated by cdk8-containing mediator complexes [J].

Akoulitchev, S ;

Chuikov, S ;

Reinberg, D .

NATURE, 2000, 407 (6800) :102-106

[2] Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27(KIP1) [J].

Aktas, H ;

Cai, H ;

Cooper, GM .

MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (07) :3850-3857

[3] Cyclin E and c-Myc promote cell proliferation in the presence of p16(INK4a) and of hypophosphorylated retinoblastoma family proteins [J].

Alevizopoulos, K ;

Vlach, J ;

Hennecke, S ;

Amati, B .

EMBO JOURNAL, 1997, 16 (17) :5322-5333

[4]

Alexander SPH, 2017, BRIT J PHARMACOL, V174, pS272, DOI [10.1111/bph.13882, 10.1111/bph.13877]

[5] Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sites [J].

Allaway, Robert J. ;

Fischer, Dawn A. ;

de Abreu, Francine B. ;

Gardner, Timothy B. ;

Gordon, Stuart R. ;

Barth, Richard J. ;

Colacchio, Thomas A. ;

Wood, Matthew ;

Kacsoh, Balint Z. ;

Bouley, Stephanie J. ;

Cui, Jingxuan ;

Hamilton, Joanna ;

Choi, Jungbin A. ;

Lange, Joshua T. ;

Peterson, Jason D. ;

Padmanabhan, Vijayalakshmi ;

Tomlinson, Craig R. ;

Tsongalis, Gregory J. ;

Suriawinata, Arief A. ;

Greene, Casey S. ;

Sanchez, Yolanda ;

Smith, Kerrington D. .

ONCOTARGET, 2016, 7 (13) :17087-17102

[6] The history and future of targeting cyclin-dependent kinases in cancer therapy [J].

Asghar, Uzma ;

Witkiewicz, Agnieszka K. ;

Turner, Nicholas C. ;

Knudsen, Erik S. .

NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (02) :130-146

[7] Racial Disparity in Gastrointestinal Cancer Risk [J].

Ashktorab, Hassan ;

Kupfer, Sonia S. ;

Brim, Hassan ;

Carethers, John M. .

GASTROENTEROLOGY, 2017, 153 (04) :910-923

[8]

ASIEDU C, 1995, CANCER RES, V55, P3716

[9] Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors [J].

Aspeslagh, Sandrine ;

Shailubhai, Kunwar ;

Bahleda, Rastilav ;

Gazzah, Anas ;

Varga, Andrea ;

Hollebecque, Antoine ;

Massard, Christophe ;

Spreafico, Anna ;

Reni, Michele ;

Soria, Jean-Charles .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (06) :1257-1265

[10] 5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma [J].

Assaf, Elias ;

Verlinde-Carvalho, Muriel ;

Delbaldo, Catherine ;

Grenier, Julien ;

Sellam, Zineb ;

Pouessel, Damien ;

Bouaita, Linda ;

Baumgaertner, Isabelle ;

Sobhani, Iradj ;

Tayar, Claude ;

Paul, Muriel ;

Culine, Stephane .

ONCOLOGY, 2011, 80 (5-6) :301-306

← 1 2 3 4 5 6 7 8 9 10 →